laquinimod
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Laquinimod is an orally dosed immuno-modulator currently under development for Huntington’s disease (HD). Preclinical findings…
MS diagnosis and prognosis is based on a combination of clinical criteria, MRI, and CSF findings. However, we still lack the…
Objective: To test whether Toll-like receptor (TLR) signaling plays a key role for reduced nuclear factor B (NF-κB) activation…
Laquinimod is a novel orally administered drug for the treatment of relapsing remitting multiple sclerosis (RRMS). In this…
The most significant data presented at the 28th Congress of the European Committee for Treatment and Research in Multiple…
Introduction: MS is a chronic immunological disease of the CNS. Due to a lack of curative treatment approaches, current…
5-Chloro-N-ethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide (laquinimod, 2) is an oral drug in clinical…
Multiple sclerosis (MS) is an inflammatory, demyelinating disorder of the central nervous system (CNS) characterized by focal…